loading...| Preferred Name |
eculizumab |
|
| Synonyms |
monoclonal antibody anti-C5 |
|
| Definitions |
A human monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C48386" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48386" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000415541 |
|
| altLabel |
monoclonal antibody anti-C5 Alexion h5G1.1 Soliris monoclonal antibody 5G1.1 |
|
| cui |
C1744173 C1541483 C1959617 C5399949 C5201119 |
|
| DATE FIRST PUBLISHED |
2005-01-24 |
|
| Date last modified |
2008-10-15 |
|
| definition |
A human monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C48386" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48386" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C48386 |
|
| notation |
CDR0000415541 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
eculizumab |
|
| tui |
T116 T129 T121 |